What's Happening

A two-drug combination of bictegravir (BIC) and lenacapavir (LEN), this drug is indicated as a complete regimen for the treatment of HIV-1 to replace the current antiretroviral regimen in those who are virologically suppressed on a stable antiretroviral regimen with no known suspected resistance to the individual components of Bixlenvo

A GLP-1 receptor agonist, this drug was previously approved as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes, this drug has now been approved to reduce the risk of major adverse cardiovascular (CV) events – including CV death, non-fatal myocardial infarction, and non-fatal stroke – in patients with type 2 diabetes who are at high risk for these events

An ACE inhibitor indicated for the treatment of hypertension, acute myocardial infarction, and adjunct therapy for heart failure, this drug received its first generic approval

Indicated for the treatment of hypertension, to lower blood pressure in adults.

Indicated for the management of anxiety disorders or for the short-term relief of the symptoms of anxiety, this is the first generic approval of the injection formulation

Indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia, including heterozygous familial hypercholesterolemia (HeFH).

A first-time generic, this drug is indicated for the management of pain severe enough to require an opioid analgesic and for which alternative treatments are inadequate

A single inhaler triple therapy that contains inhaled corticosteroids, a long-acting beta agonist (LABA), and a long-acting muscarinic antagonist (LABA), this drug is indicated for the maintenance treatment of asthma

A biosimilar to Simponi (golimumab), this drug is indicated for the treatment of moderately to severely active rheumatoid arthritis in combination with methotrexate, and moderately to severely active ulcerative colitis

A GLP-1 receptor agonist indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in adults with obesity or adults with overweight in the presence of at least one weight-related comorbid condition

A first-time generic indicated for the treatment of idiopathic pulmonary fibrosis, chronic fibrosing interstitial lung diseases (ILDs) with a progressive phenotype, and to slow the rate of decline in pulmonary function in patients with systemic sclerosis-associated ILDs

Indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus, to reduce the risk of hospitalization for heart failure in adults with type 2 diabetes mellitus and either established cardiovascular disease or multiple cardiovascular risk factors, to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure

An inhaled corticosteroid indicated for the maintenance treatment of asthma as a prophylactic therapy, and for the treatment of asthma in patients requiring oral corticosteroids

Indicated to increase bone mass in postmenopausal women with osteoporosis at high risk of fracture, in men with osteoporosis at high risk of fracture, in men and women with glucocorticoid-induced osteoporosis with high risk of fracture, in men at high risk of fracture receiving androgen deprivation therapy to nonmetastatic cancer, and in women at high risk of fracture receiving adjuvant aromatase inhibitor therapy for breast cancer

Indicated for the treatment of partial-onset seizures